Use of TLR9 and TLR7/8 agonists in combination with D-galactosamine in exploring models for distinct severities of systemic inflammation relative to liver injury

Reiko Seki* and Kazuhisa Nishizawa
Teikyo University School of Medical Technology

(*) corresponding author

Summary
Challenges with various TLR ligands (TLRLs) in combination with D-galactosamine (GalN) in rodents may mimic diverse conditions of acute inflammation and organ failure. Here, we report that CpG (ODN1826, TLR9 agonist)/GalN induced a liver-specific injury with modest systemic effects, whereas R848 (resiquimod, TLR7/8 agonist)/GalN exhibited systemic and liver toxicity. We also observed the protective effect of Gr-1⁺ cells (the population containing neutrophils) against liver injury in both the R848/GalN and CpG/GalN models. In cytokine measurements, the intraperitoneal administration of antibodies showed a non-specific tolerance induction effect, which was more pronounced in the CpG/GalN than in the R848/GalN model. Cytokine analyses also suggested that the TLR9 agonist/GalN induced a limited degree of systemic inflammation compared to TLR7/8 agonist/GalN models. The relevance of this finding to the TLR9-mediated induction of stress tolerance (protective effect) in non-immune cells is discussed.

Abbreviation: GalN, D-galactosamine; TLR, toll-like receptor; CpG, cytosine-guanosine dinucleotide; ODN, oligodeoxynucleotides; CK, creatine kinase; Ab, antibody
Introduction

Administration of lipopolysaccharide (LPS) in combination with GalN is a widely studied model for acute liver failure and inflammation-mediated organ injury (e.g., Kemelo et al. 2017). GalN can impede uridine metabolism, possibly inducing cell stress. Various TLR ligands (TLRLs) in combination with GalN can induce liver injury (Seki 2017). Both TLR7/8 and TLR9 are endosomal receptors, but in our experiments, R848/GalN induced more severe signs of illness as compared to CpG/GalN, despite the use of the doses inducing similar levels of liver injury (Seki 2017). In this study we further compared these models.

Methods

Severe extrahepatic effects of TLR7/8 but not TLR9 agonist in galactosamine mice model

To further compare the models, we measured several serum biomarkers for the mice treated with PBS, LPS, R848/GalN, and CpG/GalN. The serum alanine aminotransferase (ALT) level showed similar increases in the R848/GalN and CpG/GalN models (Figure 1A). For most biomarkers other than ALT, the CpG/GalN model did not show notable increases except for CK, and showed lower values relative to the R848/GalN model (Figure 1B-G). Thus, at the doses causing a similar level of

...
liver injury, R848/GalN induced systemic responses, whereas CpG/GalN exerted more liver-specific effects. LPS mice showed a pattern of multiple organ injury with modest liver injury.

**Blocking analysis supports protective roles of neutrophils**

For further comparison, we conducted Ab-blocking/depletion analyses focusing on neutrophils and platelets. The depletion of Gr-1$^+$ cells exacerbated liver injury compared to the pretreatment with the isotype-matched control in the R848/GalN model (Figure 2B). Consistent with this, IL-6 levels were higher in the Gr-1$^+$ cell-depleted mice compared to those in the isotype-matched control (Figure 2E). Following the IL-6 rise, IL-10 increased in Gr-1$^+$-depleted R848/GalN mice (7 h of Figure 2F). Thus, the depletion of Gr-1$^+$ cells caused aggravation of inflammation and liver injury in the R848/GalN model. Interestingly, previous studies have demonstrated the protective/anti-inflammatory effect of Gr-1$^+$ cells (or neutrophils) (Steinshamn *et al.* 1995. Omert *et al.* 1998. Daley *et al.* 2005.).

**Non-specific tolerance induction by antibody injection: proneness of TLR9 pathway to tolerance induction**

Depletion of Gr-1$^+$ cells led to a modest aggravation of liver injury in the CpG/GalN model (Figure 2B) and a marked decrease in IL-6 level (Figure 2E), lowering the IL-6/IL-10 ratio (to <1.0 at 7 h), suggestive of the tolerance (anti-inflammatory) state at 7 h (Figure 2E,F). Notably, this tolerance induction was observed even with the control Ab, suggesting a non-specific anti-inflammatory effect of Ab injection. From our experience, IL-6 levels typically reached ~5 ng/ml at 7 h in this CpG/GalN model without pretreatment, but it remained <0.5 ng/ml in the Ab-pretreated CpG/GalN mice (either anti-Gr-1$^+$ or isotype-matched control) (Figure 2E,F). This non-specific tolerance-inducing effect of Ab was not clear in the R848/GalN model, but significant in the CpG/GalN model based on IL-6 levels at 1 and 7 h.

P-selectin is considered important for leukocyte recruitment and hepatocellular injury in endotoxemic mice (Klintman *et al.* 2004). However, the blocking with anti-P-selectin Ab tended to aggravate liver injury relative to the isotype-matched control for both models (Figure 2C), suggesting a protective role of P-selectin. Cytokine analysis
showed no clear effects of anti-P-selectin Ab; however, both control and anti-P-selectin Ab caused low IL-6/IL-10 ratio, suggesting tolerance-inducing effects (Figure 2G,H). This effect was more pronounced for the CpG/GalN model than for the R848/GalN model. Interestingly, without Ab pretreatment, the IL-6/IL-10 ratio exceeded 10 (typically, IL-6 levels reached ~5 ng/mL and IL-10 ~0.3 ng/mL) at 7 h in the CpG/GalN model (Seki and unpublished data), but with the pretreatment, the ratio remained <1 (Figure 2G,H).

When the effect of platelet depletion was examined, its effect on liver injury was not consistent between the models (Figure 2D). However, for both models, the tolerance-inducing effect of both the anti-platelet and control serum was observed (Figure 2A,D,I,J). Once again, the tolerance-inducing effect based on the IL-6/IL-10 ratio was more pronounced in the CpG/GalN model (Figure 2I,J). The mechanism underlying this effect of “rabbit” serum is presently unknown; however, as shown in murine model analyses of intravenous immunoglobulin therapy, if the recognition of sialic acid on Fc by SIGN-R1 plays a key role (Tjon et al. 2015), this may explain this cross-species phenomenon. Overall, the Ab/serum pretreatment generally induced tolerance based on the low IL-6/IL-10 ratio, and this effect was more pronounced in the CpG/GalN model. In the R848/GalN model, suppression by Ab/serum of IL-6 and IL-10 was modest, with the IL-6 levels being comparable between the mice with and without pretreatment (data not shown). However, further characterization of the tolerance induction by the control Ab/serum in the future is necessary.

**Difference in systemic toxicity between the TLR7/8 and TLR9 agonists - Discussion**

The R848/GalN and CpG/GalN models showed similar levels of increase in serum levels of TNF-α, an early inflammatory mediator (Seki 2017). Without Ab pretreatment, the CpG/GalN model induced higher serum IL-6 levels (~5 ng/ml at 7 h) relative to the R848/GalN model (~0.5 ng/mL) (Seki 2017). Why did the CpG/GalN model exhibit modest systemic inflammation (Figure 1) and proneness to tolerance induction relative to the R848/GalN model (Figure 2)? One possibility is that TLR9 signaling has a more significant impact on the liver relative to TLR7/8. Notably, TLR9 has been implicated in several liver diseases (Arrese et al. 2016, Imaeda et al. 2009, Bakker et al. 2015), whereas, to our knowledge, corresponding studies on TLR7/8 are limited. Another
possibility is the limited systemic effect of the TLR9 agonist due to the protective functions of TLR9 in non-immune cells. TLR9 has been shown to contribute to cellular protection by reducing energy substrates and activating AMP-activated protein kinase (AMPK), subsequently inducing stress tolerance (Shintani et al. 2014). The TLR9/AMPK pathway can promote autophagy, which is crucial for cell protection (Ye et al. 2018). Possibly, efficient mechanisms responsible for tolerance toward TLR9 agonists have evolved to adjust TLR9 response to endogenous ligands, including mitochondrial DNA. Of note, pretreatment with lipoteichoic acid induced tolerance in CpG/GalN better than that in the R848/GalN model (Seki, 2017).

**Conclusion**

This study showed that the CpG/GalN insult induced more liver-focused injury compared to R848/GalN, which caused systemic and liver injuries, and also suggested that the tolerance induction by Ab/serum pretreatment was more pronounced for the CpG/GalN insult. Further analyses of the protective effects of TLR9 on various cells and induction of tolerance toward TLR9 signaling are warranted.

**Acknowledgement**

This work was supported by a Grant-in-Aid for Scientific Research from the Ministry of Education, Science and Culture, Japan.

**References**

ARRESE M, CABRERA D, KALERGIS AM, FELDSTEIN AE: Innate Immunity and Inflammation in NAFLD/NASH. *Dig Dis Sci* **61**:1294–1303, 2016.

BAKKER PJ, SCANTLEBERY AM, BUTTER LM, CLAESSEN N, TESKE GJD, VAN DER POLL T, FLORQUIN S, LEEMANS JC: TLR9 mediates remote liver injury following severe renal ischemia reperfusion. *PloS One*, 10: e0137511, 2015.
DALEY JM, REICHNER JS, MAHONEY EJ, MANFIELD L, HENRY JR WL, MASTROFRANCESCO B, ALBINA JE: Modulation of macrophage phenotype by soluble product(s) released from neutrophils. *J Immunol* **174**: 2265–2272, 2005.

IMAEDA AB, WATANABE A, SOHAIL MA, MAHMOOD S, MOHAMADNEJAD M, SUTTERWARA FS, FLAVELL RA, MEHAL WZ: Acetaminophen-induced hepatotoxicity in mice is dependent on Tlr9 and the Nalp3 inflammasome. *J Clin Invest* **119**: 305-314, 2009.

KEMELO MK, KUTINOVÁ CANOVÁ N, HORINEK A, FARGHALI H: D-galactosamine/lipopolysaccharide-induced hepatotoxicity in rats: involvement of sirtuin 1 and heme oxygenase 1. *Physiol Res.* **66**:497-505, 2017

KLINTMAN D, LI X, THORLACIUS H: Important role of P-selectin for leukocyte recruitment, hepatocellular injury, and apoptosis in endotoxemic mice. *Clin Diagn Lab Immunol* **11**: 56-62, 2004.

OMERT L, TSUKADA K, HIERHOLZER C, LYONS VA, CARLOS TM, PEITZMAN AB, BILLIAR TR: A role of neutrophils in the down-regulation of IL-6 and CD14 following hemorrhagic shock. *Shock* **9**: 391–396, 1998

SEKI R: Toll-Like Receptor Ligand-Induced Liver Injury in D-Galactosamine-Sensitized Mice: Differences between TLR7/8 and TLR9 Ligands, Cytokine Patterns, and Cross-Tolerance Induction by TLR2 Ligand Pretreatment. *J Immunol Res*, 2017: ID 9653793, 2017

SHINTANI Y, DREXLER HC, KIOKA H, TERRACCiano CM, COPPEN SR, IMAMURA H, AKAO M, NAKAI J, WHEELER AP, HIGO S, NAKAYAMA H, TAKASHIMA S, YASHIRO K, SUZUKI K: Toll-like receptor 9 protects non-immune cells from stress by modulating mitochondrial ATP synthesis through the inhibition of SERCA2. *EMBO reports* **15**: 438-445, 2014
STEINSHAMN S, BEMELMANS MH, BUURMAN WA, WAAGE A: Granulocytopenia reduces release of soluble TNF receptor p75 in endotoxin-stimulated mice: a possible mechanism of enhanced TNF activity. Cytokine 7: 50–56, 1995.

TJON AS, VAN GENT R, GEITENBEEK TB, KWEKKEBOOM J: Differences in anti-inflammatory actions of intravenous immunoglobulin between mice and men: more than meets the eye. Frontiers Immunol 6: 197, 2015

YE L, FENG Z, DOYCHEVA D, MALAGUIT J, DIXON B, XU N, ZHANG JH, TANG J: CpG-ODN exerts a neuroprotective effect via the TLR9/pAMPK signaling pathway by activation of autophagy in a neonatal HIE rat model. Exp Neurol 301: 70-80, 2018.

Legends for Figures

**Figure 1** Serum clinical biomarker analysis. (A-G) ALT, creatine kinase (CK), blood urea nitrogen (BUN), creatinine (Cre), total bilirubin (T-bil), direct-bilirubin (D-bil) and amylase (AMY) in serum samples of PBS, LPS, CpG/GalN, and R848/GalN-injected mice.

**Figure 2** Blocking/depletion analyses. The serum levels of ALT (A–D), IL-6 (E,G,I), and IL-10 (F,H) in serum samples of PBS, LPS, CpG/GalN, and R848/GalN-injected mice.
Figure 1
Figure 2

**A** TLR/GalN

**B** Anti-Gr-1

**C** Anti-P-selectin

**D** Anti-platelet serum

**E** Anti-Gr-1

**F** IL-6

**G** IL-10

**H** IL-6 / IL-10 ratio

| Treatment     | Time (h) | IL-6 (ng/mL) | IL-10 (ng/mL) | IL-6 / IL-10 ratio (mean ± SD) |
|---------------|----------|--------------|---------------|---------------------------------|
| R848/GalN     | 0        | 0.2 ± 0.4    | 0.2 ± 0.1     | 0.1 ± 0.0                       |
| α-Gr-1        | 1        | 0.4 ± 0.6    | 0.4 ± 0.0     | 1.0 ± 0.0                       |
| Cpg/GalN      | 0        | 0.4 ± 0.6    | 0.4 ± 0.0     | 1.0 ± 0.0                       |
| α-Gr-1        | 1        | 0.4 ± 0.6    | 0.4 ± 0.0     | 1.0 ± 0.0                       |
| Anti-P-selectin | 0       | 0.2 ± 0.4    | 0.2 ± 0.1     | 0.1 ± 0.0                       |
| R848/GalN     | 1        | 0.4 ± 0.6    | 0.4 ± 0.0     | 1.0 ± 0.0                       |
| α-P-selectin  | 1        | 0.4 ± 0.6    | 0.4 ± 0.0     | 1.0 ± 0.0                       |
| Cpg/GalN      | 0        | 0.4 ± 0.6    | 0.4 ± 0.0     | 1.0 ± 0.0                       |
| α-P-selectin  | 1        | 0.4 ± 0.6    | 0.4 ± 0.0     | 1.0 ± 0.0                       |
| Anti-platelet serum | 0   | 0.2 ± 0.4    | 0.2 ± 0.1     | 0.1 ± 0.0                       |
| R848/GalN     | 1        | 0.4 ± 0.6    | 0.4 ± 0.0     | 1.0 ± 0.0                       |
| α-platelet serum | 1    | 0.4 ± 0.6    | 0.4 ± 0.0     | 1.0 ± 0.0                       |

**I** Anti-platelet serum

| Treatment     | Time (h) | IL-6 (ng/mL) | IL-10 (ng/mL) | IL-6 / IL-10 ratio (mean ± SD) |
|---------------|----------|--------------|---------------|---------------------------------|
| R848/GalN     | 0        | 0.2 ± 0.4    | 0.2 ± 0.1     | 0.1 ± 0.0                       |
| α-platelet serum | 1    | 0.4 ± 0.6    | 0.4 ± 0.0     | 1.0 ± 0.0                       |
| Cpg/GalN      | 0        | 0.4 ± 0.6    | 0.4 ± 0.0     | 1.0 ± 0.0                       |
| α-platelet serum | 1    | 0.4 ± 0.6    | 0.4 ± 0.0     | 1.0 ± 0.0                       |